Pharmaceutical Business Confidence
Report Q1 2014 is a new report that analyzes pharmaceutical industry executives
views on the global economy, expectations on customer confidence, supplier
prices, key business concerns, and how executives’ future investments are set
to change in Q1 2014. This report also gives you access to regional analysis of
industry outlook, industry and company growth prospects, future opportunities,
staff hiring, and sales performance. Apart from providing access to the
opinions and strategies of global pharmaceutical industry executives, it also
examines their actions surrounding business priorities, threats and
opportunities, and future investment areas over the next six months. Moreover,
this report provides a comparative analysis of survey results with Q4 2013
wherever applicable.
Introduction
and Landscape
Why
was the report written?
This report is the result of an
extensive survey drawn from Kable’s exclusive panel of leading global
pharmaceutical industry executives. The report analyzes current economic
conditions prevailing across the globe and their impact on the pharmaceutical
industry, and forecasts company and industry growth prospects over the next six
months. Furthermore, it provides information about the impact of customer
confidence, supplier prices, and staff headcount likely to affect the
investment decisions of the industry over the next six months. Additionally,
this report tracks the change in executives’ perceptions during the last three
months, by providing a comparative analysis of survey results with the previous
quarter.
What
is the current market landscape and what is changing?
Overall, 74% and 60% of global
pharmaceutical industry executives are optimistic about the future growth
prospects of both their company and the industry, respectively, over the next
six months. Optimism towards company and industry growth prospects has improved
by eight and ten percentage points, respectively, in Q1 2014, compared to Q4
2013 results.
What
are the key drivers behind recent market changes?
Optimism towards industry and company
growth is driven by the improving global economic conditions, investments in
emerging markets, and the introduction of new products in the market.
What
makes this report unique and essential to read?
'Pharmaceutical Business Confidence
Report Q1 2014' is a new report by Kable that analyzes the industry sentiments
globally on the latest economic and customer issues and their impact upon
investment decisions and growth prospects within the pharmaceutical industry.
This report also examines the executive opinion about the current and future
state of the economy and its retrospective effect on the industry. Furthermore,
it analyzes the likely effect of supplier price changes, sales performance, and
staff headcount within the industry over the next six months. In addition, it
provides an overview of the key priorities, threats, and opportunities for the
global pharmaceutical industry over the next six months. Furthermore, it also
tracks the change in industry executives’ thought process, by providing a
comparative analysis of survey results with Q4 2013, wherever applicable.
Key
Features and Benefits:
- Project industry trends and industry growth expectations in the next six months, and understand business confidence to make informed business decisions.
- The report drives revenues by understanding future product investment areas and key growth regions.
- Readers will be provided with a clear uncovering of key challenges and opportunities, and identify the key priorities likely to affect growth prospects of the industry.
- The report clearly forecasts the change in supplier prices for various products, which are likely to influence the industry’s growth prospects over the next six months.
- Identifies the major changes in customer confidence levels in the pharmaceutical industry over the next six months.
Key
Market Issues:
- According to pharmaceutical industry respondents, the present economic conditions in Africa and the Middle East are deemed to be unfavourable. In the Q4 2013 survey, similar opinions were recorded.
- New government proposals/legislation, competition from new entrants, state of global economy, and performance of the Eurozone are the key concerns among global pharmaceutical industry executives.
- Survey respondents forecast that supplier prices for raw materials will increase at an average of 4.1%, with those from Asia-Pacific expecting the biggest rise.
- In total, 52% of global pharmaceutical industry executives anticipate either ‘no change’ or a ‘negative’ change in customer confidence over the industry, in the next six months.
- Industry executives exhibit high levels of optimism towards company growth prospects compared to industry growth prospects, in the next six months
Key
Highlights:
- Of respondents, 66% anticipate a positive change in the global economic outlook over the next six months. In comparison to previous quarter, the percentage of respondents who expect a positive change has increased by eighteen percentage points.
- Pharmaceutical industry executives plan to increase investments in the areas of new product development and marketing in the next six months.
- Executives operating in the Rest of the World and Asia-pacific anticipate the highest average sales increase of 6.4% and 4.5%, respectively, over the next six months.
- Industry executives operating in the Rest of the World and Europe anticipate an average increase of 3.2% and 2.2%, respectively, in their current workforce.
- Executives operating across the globe consider ‘increasing sales’, ‘improving operational efficiency’, and ‘customer retention’ as key priorities over the next six months.
The report covered 6 companies- Merck
Serono, Salix Pharmaceuticals, Santarus Inc., AstraZeneca, Pearl Therapeutics, GlaxoSmithKline.
Inquiry for more information
visit:
Find All Computing and
Electronics Reports at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.